A major challenge of targeted molecular imaging and drug delivery in cancer is establishing a functional combination of ligand-directed cargo with a triggered release system. Here we develop a hydrogel-based nanotechnology platform that integrates tumor targeting, photon-to-heat conversion, and triggered drug delivery within a single nanostructure to enable multimodal imaging and controlled release of therapeutic cargo. In proof-of-concept experiments, we show a broad range of ligand peptide-based applications with phage particles, heat-sensitive liposomes, or mesoporous silica nanoparticles that self-assemble into a hydrogel for tumor-targeted drug delivery. Because nanoparticles pack densely within the nanocarrier, their surface plasmon resonance shifts to near-infrared, thereby enabling a laser-mediated photothermal mechanism of cargo release. We demonstrate both noninvasive imaging and targeted drug delivery in preclinical mouse models of breast and prostate cancer. Finally, we applied mathematical modeling to predict and confirm tumor targeting and drug delivery. These results are meaningful steps toward the design and initial translation of an enabling nanotechnology platform with potential for broad clinical applications.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4763738PMC
http://dx.doi.org/10.1073/pnas.1525796113DOI Listing

Publication Analysis

Top Keywords

drug delivery
20
nanotechnology platform
12
multimodal imaging
8
therapeutic cargo
8
cargo release
8
tumor targeting
8
drug
5
delivery
5
integrated nanotechnology
4
platform tumor-targeted
4

Similar Publications

Cervical cancer is a common tumor in women and one of the common causes of cancer death in women. Due to the aggressive and non-specific nature of traditional chemotherapy, there is a growing need for new treatment modalities. Currently, tumor immunotherapy is increasingly garnering attention as a disruptive treatment approach.

View Article and Find Full Text PDF

In recent years, the use of cationic peptides as alternative drugs with anticancer activity has received attention. In this study, the targeted release of curcumin (Cur) and CM11 peptide alone and together against hepatocellular carcinoma (HCC) was evaluated using chitosan nanoparticles (CS NPs) coated with Pres1 that target the SB3 antigen of HCC cells (PreS1-Cur-CM11-CS NPs). SB3 protein is the specific antigen of HCC and the PreS1 peptide is a part of the hepatitis B antigen, which can specifically bind to the SB3 protein.

View Article and Find Full Text PDF

Pharmacological, computational, and mechanistic insights into triptolide's role in targeting drug-resistant cancers.

Naunyn Schmiedebergs Arch Pharmacol

January 2025

Research and Enterprise, University of Cyberjaya, Persiaran Bestari, Cyber 11, 63000, Cyberjaya, Selangor, Malaysia.

As a promising candidate for tackling drug-resistant cancers, triptolide, a diterpenoid derived from the Chinese medicinal plant Tripterygium wilfordii, has been developed. This review summarizes potential antitumor activities, including the suppression of RNA polymerase II, the suppression of heat shock proteins (HSP70 and HSP90), and the blockade of NF-kB signalling. Triptolide is the first known compound to target cancer cells specifically but spare normal cells, and it has success in treating cancers that are difficult to treat, including pancreatic, breast, and lung cancers.

View Article and Find Full Text PDF

Strategies and Challenges of Cytosolic Delivery of Proteins.

J Drug Target

January 2025

Jiangsu Key Laboratory of Druggability of Biopharmaceuticals and State Key Laboratory of Natural Medicines, School of Life Science and Technology, China Pharmaceutical University, Nanjing 210009, China.

The cytosolic delivery of therapeutic proteins represents a promising strategy for addressing diseases caused by protein dysfunction. Despite significant advances, efficient delivery remains challenging due to barriers such as cell membrane impermeability, endosomal sequestration, and protein instability. This review summarizes recent progress in protein delivery systems, including physical, chemical, and biological approaches, with a particular focus on strategies that enhance endosomal escape and targeting specificity.

View Article and Find Full Text PDF

Synthesis of 4-(Bromodifluoromethylseleno) Isocoumarins via Selenolation/Lactonization of 2-Alkynylbenzoates Enabled by a Multi-Component Reagents System.

J Org Chem

January 2025

Tianjin Key Laboratory for Modern Drug Delivery & High-Efficiency, School of Pharmaceutical Science and Technology, Faculty of Medicine, Tianjin University, Tianjin 300072, China.

-CFBnSeCFBr was developed as a bromodifluoromethylselenonating reagent, which was utilized by combining with CPBA and TfO for the synthesis of 4-(bromodifluoromethylseleno) isocoumarins via the selenolation/lactonization of 2-alkynylbenzoates. The transformation was postulated to proceed via a multicomponent reagents system-enabled sequence involving the oxidation of -CFBnSeCFBr by CPBA into its selenium sulfoxide, activation of the generated sulfoxide by TfO into the electrophilic -CFBnSeOCFBr salt, and selenolation/lactonization of 2-alkynylbenzoates by the reactive electrophilic species into 4-(bromodifluoromethylseleno) isocoumarins.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!